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Summary Six different immunisation regimes have been used to generate spleen cells with reactivity against
human pancreatic exocrine cancer. Immunised spleen cells were fused with an NSO/1 myeloma line and
supernatants from these hybridomas selectively screened for monoclonal antibodies which bound
predominantly to a pacreatic cancer cell line (GER). The spleen cells from hairy litter mates immunised with
pancreatic cancer xenograft homogenates and viable GER cells generated 13% of hybridoma supernatants
which showed some selectivity for GER pancreatic cancer cells in a fixed cell ELISA assay. The other
methods produced only 4% of hybrids with selectivity for GER cells. The antigen distribution on
gluteraldehyde fixed cells was similar to that found for viable cell monolayers but many antigens were
unstable on formalin fixation. Immunohistochemical staining of GER cells grown on glass slides showed a
heterogeneity of antigen distribution with up to 70% of the cells exhibiting a vesicular pattern of staining.
Fifty percent of the antibodies which bound to GER cells were also reactive against antigens in formalin-fixed
paraffin-embedded tissue sections of the original GER tumour. Monoclonal antibody DD9E7 identified an
antigen expressed on 12/14 pancreatic adenocarcinomas. The antibody showed strong staining of malignant
luminal membrances and cytoplasm. The antigen was also present in normal salivary and sweat glands, and
colon and breast carcinomas, but its tissue distribution was unlike that of CEA or EMA. The expression of
this antigen in 12/14 of pancreatic carcinomas suggests that DD9E7 may be a useful reagent for pancreatic
tumour detection.
As with many of the other common solid cancers,
the availability of an antibody with 'useful
selectivity' for pancreatic exocrine adenocarcinoma
would contribute significantly to diagnostic and
therapeutic possibilities. A monoclonal antibody
Cal9-9, prepared against a colon carcinoma cell
line, has been shown to bind to pancreatic cancer,
as well as other gastroinstestinal cancer tissue
sections (Atkinson et al., 1982), but only two
groups have focussed on the pancreas itself as the
source of immunogen. Metzgar et al., (1982) have
produced a number of monoclonals against
ductular epithelium and tumour tissue using a
pancreatic tumour cell line, and Parsa et al. (1982)
have prepared a monoclonal against normal
pancreatic duct cells and indentified the antigen on
foetal and adult normal pancreas, as well as
pancreatic tumours and cell lines.
A possible route to the production of selective
antibodies was suggested by our earlier work
(Grant & Duke, 1981; Davies et al., 1983; Mathews
et al., 1984). This showed that human cancer-cell
components shed into the circulation of nude
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animals bearing human tumour xenografts will
stimulate the production of antibodies when this
serum is injected into immunocompetent hairy litter
mates. When serum was taken from animals
bearing pancreatic tumour xenografts, the anti-
bodies produced in the hairy litter mates were
predominantly selective for pancreatic cancer cells
GER (Grant & Duke, 1981). In the present study,
we have looked at this and five other procedures
for generating spleen cells with reactivity against
pancreatic cancer. One of these regimes, combined
with a selective screening assay for antibodies which
bind predominantly to pancreatic cancer cells, has




Human pancreatic exocrine adenocarinoma cell
lines GER (Grant et al., 1979) and WAD (Davies
et al., 1983); colon carcinoma cell lines AC and EC
(Walton et al., 1985), and HT29 (Fogh & Trempe,
1975); renal carcinoma GYL (Matthews et al.,
1982); bladder carcinoma RT4 (Rigby & Franks,
©) The Macmillan Press Ltd., 1985544 A.G. GRANT et al.
1970) breast carcinoma MDA-157 (Young et al.,
1973) and a fibrosarcoma HT1080 (Rasheed et al.,
1974) were provided by the originators except for
HT-29 (C. O'Toole) and MDA-157 (P. Beverley)
and HT1080 (Flow Laboratories). All cell lines
were maintained in Ham's F12 supplemented with
10% FCS 1 mM glutamine, 200 4ugml-1 penicillin,
50ygml-1 streptomycin and passaged with 0.02%
EDTA in Ca"+ and Mg"+ free Earle's balanced
salt solution (Flow). Human lymphocytes (HL)
were freshly isolated from pooled buffy coat residue
(A and 0 groups) of normal volunteers by Ficoll-
paque (Pharmacia) separation. Myeloma line
NSO/l (Galfre & Milstein, 1981) was grown in
Dulbecco's modified Eagle's medium+10% horse
serum, 5% FCS, 1 mm glutamine, 200Mgml1
penicillin and 50 gml 1 streptomycin (Gibco).
Animals
Outbred congenitally athymic 'nude' mice (nu/nu)
and nude beige mice (nu/nu-bg/bg, T and NK cell
deficient; A. Sebesteny ICRF, personal communi-
cation) were obtained from the ICRF laboratories
(Mill Hill, UK) and housed in germ-free negative
pressure isolators. Hairy litter mates (nu/+; HLM)
and BALB/c mice were bred at St. George's
Hospital Medical School, and maintained in conven-
tional conditions. Human tumour xenografts from
a pancreatic carcinoma (GER) were established as
previously described (Grant et al., 1979).
Immunisation procedures
1. Cell lines were detached with 0.02% EDTA in
Ca` and Mg` free PBS and 1 x 107 cells
injected s.c. and at days 0 and 21, and i.p. at
day 42, into BALB/c mice. Spleens were
removed for fusion 3 days later.
2. Nude mouse xenografts were removed when the
tumour measured 2cm2, homogenised, three-
quarters passaged into other nude animals and
the remainder injected s.c. into either (a)
BALB/c mice or (b) nude mice hairy litter mate
relatives (nu/+ -HLM). Animals were boosted
with xenograft tumour homogenate after 14 and
28 days and with further xenograft tumour or
5 x 10' GER cells 3 days prior to fusion.
3. Spleens were taken directly from human
pancreatic tumour-bearing nude mice and used
for fusion when the tumour measured 2cm2.
4. Serum from pancreatic tumour-bearing nude
mice (tbnm serum) was used to immunise HLM
as described previously (Grant & Duke, 1981).
Four weeks after the last boost, the animals
were injected i.p. with 0.4ml tbnm serum and
spleens taken for fusion 3 days later.
5. Two irradiated BALB/c mice (5Gy whole body
X-ray ICRF) were reconstituted with an i.p.
injection of 1 x 107 HLM spleen cells, from
animals immunised as in 4. above, together with
0.2ml tbnm serum given either i.p. or i.v.
Spleens were taken for fusion 2, 6 and 7 days
after i.v. injection, 7 and 9 days after i.p.
injection, or 3 days after a further i.p. boost.
Mouse antiserum against pooled, normal
lymphocytes (MHL) was prepared as previously
described (Grant & Duke, 1981).
Fusion
Cell fusion was carried out essentially according to
published methods (Kohler & Milstein, 1975;
Galfre et al., 1977). Hybrids were diluted in HAT
medium (Gibco) +15% FCS to lx105 cellsml-I
and plated out in 96 well (Costar) plates. Hybrids
which produced antibody were cloned by limiting
dilution into 96 well plates or single clones were
removed with a micropipette into 24 well plates
containing a feeder layer of mouse spleen cells
(1 x 104 per well). Hybrids were stored in liquid
nitrogen in 90% FCS 10% DMSO. Large quantities
of immunoglobulin (Ig) were prepared by injecting
1 x 107 hybridoma cells i.p. into nude beige mice
(nu/nu-bg/bg). Ascitic fluid was collected after 10-14
days and IgG separated by affinity chromatography
on protein-A Sepharose (Pharmacia).
Screening ofhybridoma supernatants
Hybridoma supernatants (10-20 days after fusion)
were tested for Ig production against tumour cells
usingsheepanti-mouse Igureaseconjugated antibody
(SAMIg) in a modified ELISA assay (Sera Labs).
Tumour cells (5 x 104 per well) or lymphocytes
(105 per well) were added to poly-L-lysine treated
96 well PVC plates (Titertek-Flow) and fixed with
0.05% glutaraldehyde (Suter et al., 1980; Cobbold
& Waldmann, 1981), or 10% formaldehyde in
PBS. (The plates could be stored in PBS containing
1% FCS, 0.25% BSA, 0.05% Tween 20 and 0.02%
sodium azide for one month at 4°C). Viable cells
were grown on y-irradiated PVC plates (Titertek)
for 24-48h to obtain a confluent monolayer,
washed and used immediately. Following 30-60min
incubation with 50pl hybridoma supernatant at
room temperature, cells were washed with 0.05%
Tween 20 in PBS and incubated with 50jl SAMlg
(1:250 dilution) for 1 hr 37°C. After extensive
washing in PBS and H20, the colour was developed
with 50pd urease substrate. The reaction was
stopped by the addition of 20jl 1% w/v thiomersal
and plates read at 588nM on a Titertek Multiscan.
Mouse antiserum against pooled normal human
lymphocytes (MHL) and HAT medium were used
as positive and negative controls respectively.
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antibody binding to glutaraldehyde fixed pancreatic
carcinoma cells GER. Positive wells (the colour
change was associated with an OD of >0.07) were
rescreened against glutaraldehyde fixed HT29, GYL
and HL. Only wells which were predominantly
reactive against GER were cloned. Ig subclass was
determined by ELISA assay using 1/100 dilution
goat anti-mouse IgGl, IgG2a, IgG2b, IgA and IgM
(Nordic Immunological Labs).
Immunocytochemical localisation
Hybridoma supernatants were tested on formalin
fixed paraffin embedded tissue sections using the
indirect immunoperoxidase technique (Heyderman,
1985) and an affinity-purified goat anti-mouse
conjugate (Amersham International, UK). Endo-
genous peroxidase was inhibited by a sequence of
6.0% hydrogen peroxide, 2.5% periodic acid and
0.02% potassium borohydride (Heyderman, 1979).
Supernatants of interest were screened on a wide
range of normal and malignant tissue sections, and
compared with the pattern of staining found with
monoclonal antibodies against CEA (Amersham
International), epithelial membrane antigen EMA
(Heyderman et al., 1985) and a monoclonal
antibody against the shared CEA/NCA determinant
(Mab 122, Dr Mach, Lausanne).
Results
Comparison ofimmunisation regimes
Thirty successful fusions were carried out using 6
different immunisation regimes. As can be seen in
Table I, in all but one of the immunisation methods
(HLM immunised with tbnm serum), over 70% of
the wells produced hybrid clones. In general, 1-3
discreet clones were produced in each well. These
could be individually removed with a micropipette
and grown up for further cloning by limiting
dilution. This method proved to be more successful
than cloning by limiting dilution in the first
instance.
The largest percentage of hybrid containing wells
producing antibody (32%) which bound to
glutaraldehyde fixed target cells (Table 1, column 2)
was found when spleen cells from hairy litter mates,
immunised with homogenates of human pancreatic
xenografts, were fused with NSO/1 cells (method
2b). This method of immunisation also generated
many more hybridoma supernatants which were
shown to be predominantly reactive against GER
pancreatic carcinoma cells on a second screening
(13%). Spleens taken from chimaeric animals 2, 6,
and 7 days after i.v. injection of HLM spleen cells
did not produce successful fusions, even though
Table I Selectivity of immunoglobulin produced by hybrids in primary fusion following 5 different immunisation regimes
No. hybrid % Hybrid wellsproducing Ig % Hybrid wells producing Ig
Immunisation No. containing reactive against tumour reactive predominantly
regime expts. wells cells and lymphocytes? against pancreatic cells GER
1. BALB/c mice immunised
with GER cells 2 82% 16% 4%
(441/540)
2a. BALB/c mice immunised
with GER xenograft 3 74% 9% 3%
(662/900)
2b. Hairy litter mates
immunised with xenograft
& cells 3 73% 32% 13%
(747/1020)
3. Spleens from nude mice
bearing tumour xenograft 9 77% 18% 2%
(2305/3000)
4. Hairy litter mates
immunised with serum
from GER tumour-




spleen cells from (4)
above 6 70% 9% 2%
(1353/1920)
aSupernatants tested against GER, HT29, GYL, HL.
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there were large white patches of colonising spleen
cells in the spleens of these animals. Successful
fusions were obtained when spleens had been
reconstituted with i.p. injections of HLM spleen
cells and boosted with tbnm serum. When spleen
cells obtained from nude mice bearinig tumour
xenografts were fused with NSO/1 cells, 18% of the
hybridoma supernatants contained antibody
reactive against tumour cells, despite their
incomplete T cell system. However, only 2% of
these hybrids showed any selectivity for GER cells,
and this low level of selectivity was found with the
other 4 immunisation regimes.
The hybrids which produced antibodies pre-
dominantly reactive against GER cells were cloned
and their supernatants screened against a panel of
viable, formalin or glutaraldehyde fixed tumour
cells (Table II). The antibodies remained reactive
against pancreatic cancer cells, but there was also
cross-reactivity with other carcinoma cell lines. The
pattern of binding was dependent on fixation.
Glutaraldehyde fixed and viable cells showed the
same degree of binding but a number of the
antibodies did not bind to formalin fixed cells.
Spleens from mice which had been immunised with
xenograft material followed by GER cells,
produced the most stable antibodies after cloning.
Immunocytochemical screening
Fourteen selected hybridoma supernatants were
further screened on formalin fixed paraffin
embedded tissue sections. The initial screen was
carried out on normal non-neoplastic human
pancreas and blocks of the pancreatic tumour from
which the GER cell line had originally been
derived. Seven out of 14 stained pancreatic ducts
and ductules in non-neoplastic formalin-fixed
pancreatic tissue, and five of these also stained
malignant epithelium in GER pancreatic tumour.
Most of the antibodies had a similar pattern of
staining and the supernatant which showed the
most intense staining of malignant pancreatic
epithelium (DD9E7) was produced as ascitic fluid
in beige nude mice. These mice have defective
macrophages (A. Sebesteny, personal communica-
tion) and therefore do not need to be pristane
treated. The antibody was shown to be IgG2b.
Protein A purified immunoglobulin as well as
culture supernatant was tested against other
pancreatic adenocarcinomas (14), colorectal carci-
nomas (5), infiltrating ductular carcinomas of the
breast (7) and a variety of non-neoplastic and
malignant tissues. Twelve of the fourteen pancreatic
adenocarcinomas showed strong staining of their
Table II Binding of monoclonals to a panel of gluteraldehyde-fixed tumour cells and normal
human lymphocytes. Elisa assay using sheep anti-mouse urease conjugated antibody
O.D. at 588nM
Cell line
GER WAD HT29 AC EC RT4 GYL MDA HL
Monoclonal
64. A-C6 0.12a 0.02 0.04 0
65. A-G4 0.18 0.05 0.12 0.09 0.09 0.08 0
65 A-G4-F5 0.06 0.13 0.14 0.11 0.08 0.09 0.05 0.01
65. C-F11 0.07 0.02 0 0.01 0.01 0 0
C-F11-F9-B7 0.03 0.10 0.11 0.08 0.06 0.01 0
65. D-D9 0.09 0.06 0.10 0.07 0.03 0.03 0
D-D9-E7 0.10 0.03 0.06 0.07 0.01 0.05 0.01
65. F-E6/1 0.11 0.06 0.09 0.07 0.07 0.05 0.01
F-E6/1-B8 0.08 0.04 0.07 0.07 0 0.03 0.02
F-E6/1-C6 0.20 0.05 0.07 0.06 0.08 0.06 0.02
F-E6/1-F4 0.17 0.12 0.09 0.11 0.08 0.04 0.05
65. F-E6/2 0.09 0.01 0.09 0.07 0.01 0.03 0
65. F-E10b 0.06 0.05 0.10 0.06 0.09 0.10 0.04
67. C-B7 0.08 0.08 0.16 0.09 0.20 0.05 0.02 0
67. D-G9 0.09 0.15 0.16 0.14 0.11 0.11 0.07 0.04
67. F-D4 0.13 0.17 0.19 0.17 0.13 0.13 0.06 0.07
67. F-D7b 0.08 0.09 0.11 0.01 0.07 0.04 0.01 0
apositive wells had an OD<0.07.
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luminal membranes and cytoplasm (Figure 1), while
included pancreatic islets were negative and acini
and non-neoplastic ducts were often only weakly
stained (Figure 2). In colorectal carcinomas,
staining was mainly seen in the necrotic debris
within acini while many luminal membranes were
negative or only weakly stained (Figure 3). This
was unlike the luminal pattern of staining found
with a monoclonal against CEA (Figure 4). In 3/7
ductal carcinomas of the breast there was a
grandular distribution of reaction product in the
cytoplasm of a small population of tumour cells,
quite unlike the luminal pattern of staining found
with anti-EMA. DD9E7 also stained the supra-
nuclear cytoplasm in some ducts and acini of
normal human submandibular salivary gland and
showed a luminal pattern of staining in normal
colon and eccrine sweat glands. Except for included
polymorphs and macrophages, which were stained
in all sections, pituitary and placenta were negative,
as were normal thyroid and a renal cell carcinoma.
The immuno-cytochemical screening was also
extended to cell lines which had been grown on
glass slides prior to formalin fixation. The
pancreatic cell line (GER), which was used as the
immunogen, showed a heterogeneity of distribution
with up to 70% of the cells showing a distinctive
vesicular pattern of staining (Figure 5). In contrast,
a fibrosarcoma HT1080 was completely negative
(Figure 6).
Discussion
A murine monoclonal antibody (DD9E7), with
some discrimination for pancreatic adeno-
carcinomas, has been generated by the fusion of
NSO/I cells with spleens from nude mouse hairy
litter mates immunised with pancreatic tumour
xenograft and cultured cells (GER). This method
was considerably more successful than any of the
other, more standard, immunisation routes in
generating the highest proportion of supernatants
(13%) which showed some selectivity for the target
cell (GER). This may in part be due to the
homology between the nude tumour bearing host
and the immunised hairy litter mate, such that the
immunological response is only against the human
tumour cells rather than against the infiltrating
mouse stroma. It is also possible that tumour cells
growing in vivo as xenografts express antigens that
are present on the original tumour but are lost on
tissue culture, or that the transference of the mouse
cell population of the tumour xenograft to a
compatible immunocompetent host may contribute
to the antibody response of the hairy litter mates.
Using the other methods only 4% of the hybrids
produced antibody with selectivity for GER cells.
Spleens from nude mice bearing tumour xenografts
produced hybrids, despite their incomplete T cell
system, but very few antibodies showed any
selectivity. These results are similar to those
obtained using tumour bearing immune-suppressed
mice (Herlyn et al., 1983). Spleens from hairy litter
mates immunised with serum from GER tumour
bearing mice were successful at producing antibody
secreting hybrids, but again, the antibodies were
relatively unselective.
The use of a modified ELISA assay made it
possible to identify rapidly hybrid wells of potential
usefulness for cloning and subsequent immuno-
histochemical localisation studies. Glutaraldehyde
fixation of the target cells was preferred to
formaldehyde since many antigens were unstable on
formalin fixation. The reactions found on
glutaraldehyde fixation were also very similar to
those present on viable cell monolayers and may
more realistically reflect the antigen distribution in
vivo. However, the ELISA assay was limited to the
initial screening, since it could not allow for either
the heterogeneity of the cell population or
distribution of antigen on the cell surface. Immuno-
histochemical staining of GER cells showed that
-70% of the cells exhibited antigen when the cells
were approaching confluency in normal culture
conditions, and the antigen had a vesicular pattern
of distribution.
Fifty per cent of the antibodies which bound to
GER cells were also reactive against antigens
retained on formalin-fixed paraffin embedded tissue
sections. This paralleled the loss of antigen activity
found on formalin fixation of target cells in the
ELISA assay. The most intensely staining
monoclonal antibody, DD9E7, identified an antigen
which was present in large amounts in 12/14 of
pancreatic adenocarcinomas, absent from islets and
variably expressed on normal acini ducts and
ductules. The antigen was also found in colon and
breast carcinomas and a number of normal tissues
but its immunohistochemical pattern was different
to that found with antibodies against CEA or EMA
(Heyderman et al., 1979; Grahame et al., 1985).
Consistent staining of polymorphs and macro-
phages in all sections suggested the antigen may be
an NCA-like material (Mach & Putztnaseri, 1972;
Von Kleist et al., 1972). The tissue distribution of
the antigen together with preliminary studies, which
show that DD9E7 binds to a component of
- 55,00mol. w in GER cell lysates (Winterbourne &
Grant; unpublished observations), suggest that the
antigen recognised by DD9E7 is unlike the sialo-
ganglioside and mucin-like antigens recognised by
CA19-9 (Magnani et al., 1982; 1983) and Du-Pan-2
(Borowitz et al., 1984).548 A.G. GRANT et al.
Figure 1 Moderately differentiated pancreatic adeno- Figure 2 In another field of the section shown in
carcinoma stained with DD9E7 using an indirect Figure 1, a residual pancreatic islet is negative, while
immunoperoxidase technique. The cytoplasmic reactive residual non-neoplastic pancreatic ducts are weakly
cells are positive. ( x 125). stained and a small focus of tumour (bottom left) is
positive ( x 125).
Figure 3 Moderately differentiated carcinoma of the Figure 4 Another area of the same tumour as in
colon stained with DD9E7. The staining is mainly in Figure 3 stained with a monoclonal antibody to CEA.
the necrotic debris, reactive polymorphs and macro- The staining is mainly on the luminal membrane of
phages in the stroma (x 125). malignant acini, and in the necrotic debris (x 125).MONOCLONAL ANTIBODIES AGAINST PANCREATIC ADENOCARCINOMA 549
Figure 5 GER cell line grown on glass slide and
stained with DD9E7. The distinctive vesicular pattern
of staining in the cytoplasm is shown ( x 500).
This study has shown that tumour cells growing
in vivo as xenografts in nude mice are an ideal
immunogen, when injected into syngenic relatives
(nu/+), for the production of monoclonal
antibodies to pancreatic tumour cells GER. One of
these monoclonal antibodies, DD9E7, binds to an
antigen present in pancreatic carcinomas. Its
detection by DD9E7 may prove useful for both
w i~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..
Figure 6 Fibrosarcoma cell line HT1080 also grown
on slide and stained with DD9. No staining is seen
( x 500).
immunohistochemical and tumour localisation
studies, and we are currently isolating the antigen
for further biochemical analysis.
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